Although it was already known that DC trans-presentation of IL-15 was required for NK cell priming in sterile inflammation [115], the possibility to trigger this pathway by immune-modulating agents in the context of primary cancer may represent an innovative approach for cancer immunotherapies. The gene discussed is IL15; the disease is cancer.